Health service policy

Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England.

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

We spoke to 4 people about why, when it comes to cancer, every second counts and why the Government must act now to ensure the NHS can catch more cancers early.

In the last 6 years, almost 55,000 cancer patients should have been diagnosed or started their treatment sooner, according to new calculations.

The Medicines and Healthcare products Regulatory Agency has approved the first-of-its-kind drug sotorasib for some people with non small cell lung cancer.

Our chief executive, Michelle Mitchell, reflects on his cancer legacy and the challenges still facing Amanda Pritchard as she steps into the role.

We joined 46 other cancer charities to outline what we need from UK Governments and the NHS coming out of the pandemic to move towards world-leading services.

The latest cancer waiting times show an 8% drop in the number of people starting cancer treatment in January, compared with figures from January 2020.

A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.

There’s been a steady stream of figures since the pandemic began, each laying bare what many people have seen first-hand – the impact on health services.